Published on Nov 16, 2022
Two upcoming rulings by the UK’s Competition Appeal Tribunal (CAT) are expected to further clarify the price monopolist pharmaceutical companies can charge the UK’s National Health Service (NHS) for off-patent drugs, sources have told The Capitol Forum. The rulings—set to be handed down over the next couple of months—will come at a particularly sensitive time […]
Already have an account? Log in.
Copyright ©2026 The Capitol Forum. All Rights Reserved.
